Prognostic significance of autoimmunity during treatment of melanoma with interferon (Q37833559)

24 August 2017

1 reference

title

Prognostic significance of autoimmunity during treatment of melanoma with interferon (English)

1 reference

24 August 2017

Michal T Krauze

1

1 reference

24 August 2017

Ahmad Tarhini

series ordinal

2

1 reference

24 August 2017

Helen Gogas

series ordinal

3

1 reference

24 August 2017

John M Kirkwood

series ordinal

4

1 reference

24 August 2017

publication date

31 January 2011

1 reference

Seminars in Immunopathology

24 August 2017

published in

1 reference

24 August 2017

volume

33

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

385-391

1 reference

Cutaneous melanoma: public health approach to early detection

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Spontaneous regression of metastases from melanoma: review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Regulatory T cells exert checks and balances on self tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Regulatory T cells in immunologic self-tolerance and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Melanoma: a model for testing new agents in combination therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Control of autoimmunity by naturally arising regulatory CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Virus interference. I. The interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Alpha and beta interferons and their receptor and their friends and relations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0247-Y

Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses

21 January 2018

1 reference

12 December 2020

Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone

1 reference

12 December 2020

A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma

1 reference

12 December 2020

Signal transduction in the interferon system.

1 reference

12 December 2020

Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon

1 reference

12 December 2020

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

1 reference

12 December 2020

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

1 reference

12 December 2020

Antiphospholipid syndrome associated with immunotherapy for patients with melanoma

1 reference

12 December 2020

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

12 December 2020

Pharmacokinetics of peginterferons

1 reference

12 December 2020

Vitiligo and cutaneous melanoma. A case study

1 reference

12 December 2020

Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma

1 reference

12 December 2020

[Problems in defining melanoma regression and prognostic implication]

1 reference

12 December 2020

Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma.

1 reference

12 December 2020

Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy

1 reference

12 December 2020

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

1 reference

12 December 2020

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

1 reference

12 December 2020

Control of intestinal inflammation by regulatory T cells

1 reference

12 December 2020

Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma

1 reference

12 December 2020

Vitiligo in patients with metastatic melanoma: a good prognostic sign

1 reference

12 December 2020

Inhibition of growth of B16 murine malignant melanoma by exogenous interferon

1 reference

12 December 2020

Prognostic significance of hypopigmentation in malignant melanoma

1 reference

12 December 2020

10.1007/S00281-011-0247-Y

Identifiers

DOI

1 reference

24 August 2017

1 reference